Check-Cap (NASDAQ: CHEK) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Check-Cap to similar companies based off the strength of its profitability, dividends, risk, institutional ownership, earnings, valuation and analyst recommendations.

Insider and Institutional Ownership

19.3% of Check-Cap shares are owned by institutional investors. Comparatively, 66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Check-Cap and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap 0 0 3 0 3.00
Check-Cap Competitors 97 362 955 28 2.63

Check-Cap currently has a consensus price target of $6.00, indicating a potential upside of 235.20%. All “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 24.61%. Given Check-Cap’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Check-Cap is more favorable than its competitors.

Risk and Volatility

Check-Cap has a beta of -0.37, meaning that its stock price is 137% less volatile than the S&P 500. Comparatively, Check-Cap’s competitors have a beta of 0.81, meaning that their average stock price is 19% less volatile than the S&P 500.

Valuation and Earnings

This table compares Check-Cap and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Check-Cap N/A -$9.62 million -3.03
Check-Cap Competitors $2.40 billion $906.33 million 4.02

Check-Cap’s competitors have higher revenue and earnings than Check-Cap. Check-Cap is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.

Profitability

This table compares Check-Cap and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Check-Cap N/A -98.88% -80.97%
Check-Cap Competitors -538.85% -41.85% -24.81%

Summary

Check-Cap competitors beat Check-Cap on 8 of the 12 factors compared.

About Check-Cap

Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.

Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.